Crick — Clinical Intelligence Platform

Early research (Phase 1)Study completedNCT04601051

What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Who this might be right for

Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis

Intellia Therapeutics 72

Results for “Cardiomyopathy, Familial”

Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study

Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention

Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Study of AG10 in Amyloid Cardiomyopathy

Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy

Mayo AVC Registry and Biobank

Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques

Genetics of Cardiovascular and Neuromuscular Disease

Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors

Modeling and Pharmacological Targeting of Genetic Cardiomyopathy in Children Via Cardiomyocytes Derived From Induced Pluripotent Stem Cells (DMDstem)

Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients

Cardiovascular Multimodality Imaging Study

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)